Cargando…
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial
BACKGROUND: Combining the antibiotic azithromycin and hydroxychloroquine induces airway immunomodulatory effects, with the latter also having in vitro antiviral properties. This may improve outcomes in patients hospitalised for coronavirus disease 2019 (COVID-19). METHODS: Placebo-controlled double-...
Autores principales: | Sivapalan, Pradeesh, Ulrik, Charlotte Suppli, Lapperre, Therese Sophie, Bojesen, Rasmus Dahlin, Eklöf, Josefin, Browatzki, Andrea, Wilcke, Jon Torgny, Gottlieb, Vibeke, Håkansson, Kjell Erik Julius, Tidemandsen, Casper, Tupper, Oliver, Meteran, Howraman, Bergsøe, Christina, Brøndum, Eva, Bødtger, Uffe, Bech Rasmussen, Daniel, Graff Jensen, Sidse, Pedersen, Lars, Jordan, Alexander, Priemé, Helene, Søborg, Christian, Steffensen, Ida E., Høgsberg, Dorthe, Klausen, Tobias Wirenfeldt, Frydland, Martin Steen, Lange, Peter, Sverrild, Asger, Ghanizada, Muhzda, Knop, Filip K., Biering-Sørensen, Tor, Lundgren, Jens D., Jensen, Jens-Ulrik Stæhr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186006/ https://www.ncbi.nlm.nih.gov/pubmed/34083403 http://dx.doi.org/10.1183/13993003.00752-2021 |
Ejemplares similares
-
Treatment Response Biomarkers in Asthma and COPD
por: Meteran, Howraman, et al.
Publicado: (2021) -
Recent developments in the management of severe asthma
por: Meteran, Howraman, et al.
Publicado: (2022) -
Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial
por: Sivapalan, Pradeesh, et al.
Publicado: (2020) -
Risk of Malignancy in Patients with Asthma-COPD Overlap Compared to Patients with COPD without Asthma
por: Bonnesen, Barbara, et al.
Publicado: (2022) -
Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study
por: Kamstrup, Peter, et al.
Publicado: (2021)